Loading...
Idiopathic multicentric Castleman disease (iMCD) is characterized by lymphadenopathy, anemia, hypoalbuminemia, and inflammation driven by interleukin-6 (IL-6). Therapies include corticosteroids, rituximab, and monoclonal antibodies targeting IL-6 (anti-IL-6 mAb: siltuximab, tocilizumab). However, the optimal sequence of treatments and best alternative agents for nonresponders are unclear.
To draft guidelines for the management of patients with iMCD, the Castleman Disease Collaborative Network reviewed data from 344 patients, relevant publications, and expert opinion to develop a consensus statement using a modified Delphi process.
Perfor…